Back to top
more

West Pharmaceutical Services (WST)

(Delayed Data from NYSE)

$390.20 USD

390.20
427,061

+14.85 (3.96%)

Updated Apr 23, 2024 04:00 PM ET

After-Market: $390.32 +0.12 (0.03%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value B Growth B Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 29% (74 out of 252)

Industry: Medical - Dental Supplies

Better trading starts here.

Zacks News

Is a Beat Likely for West Pharmaceutical (WST) in Q1 Earnings?

West Pharmaceutical's (WST) first-quarter 2024 results are likely to reflect strength in its Proprietary Products business. However, unfavorable currency movements might have hurt the top and bottom lines.

West Pharmaceutical Services (WST) Expected to Beat Earnings Estimates: Should You Buy?

West Pharmaceutical (WST) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Reasons to Hold West Pharmaceutical (WST) in Your Portfolio Now

West Pharmaceutical (WST) continues to gain momentum due to its strength in the Proprietary Products business. However, forex concerns persist.

Merit Medical (MMSI) Down 0.6% Since Last Earnings Report: Can It Rebound?

Merit Medical (MMSI) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Why Is Henry Schein (HSIC) Down 1.8% Since Last Earnings Report?

Henry Schein (HSIC) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Reasons to Hold West Pharmaceutical (WST) in Your Portfolio Now

West Pharmaceutical (WST) continues to gain momentum due to its strength in the Proprietary Products business. However, forex concerns persist.

Strength Seen in West Pharmaceutical (WST): Can Its 5.7% Jump Turn into More Strength?

West Pharmaceutical (WST) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

West Pharmaceutical (WST) Beats on Q4 Earnings, HVP Drives Sales

West Pharmaceutical's (WST) fourth-quarter results reflect a strong demand for non-COVID-19 products, especially HVP devices.

West Pharmaceutical (WST) Reports Q4 Earnings: What Key Metrics Have to Say

Although the revenue and EPS for West Pharmaceutical (WST) give a sense of how its business performed in the quarter ended December 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

West Pharmaceutical Services (WST) Beats Q4 Earnings Estimates

West Pharmaceutical (WST) delivered earnings and revenue surprises of 2.81% and 0.93%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

Debanjana Dey headshot

Medical Products Stocks' Earnings Due on Feb 15: WST, ITGR & More

Medical Products companies' quarterly results are likely to reflect strength in customer demand. Let's see how ITGR, WST, AMN and PACB are placed ahead of their earnings releases.

BDX or WST: Which Is the Better Value Stock Right Now?

BDX vs. WST: Which Stock Is the Better Value Option?

What's in Store for West Pharmaceutical (WST) in Q4 Earnings?

West Pharmaceutical's (WST) fourth-quarter 2023 results are likely to reflect strength in the Proprietary Products business. However, unfavorable currency movements might have hurt the top and bottom lines.

Insights Into West Pharmaceutical (WST) Q4: Wall Street Projections for Key Metrics

Get a deeper insight into the potential performance of West Pharmaceutical (WST) for the quarter ended December 2023 by going beyond Wall Street's top -and-bottom-line estimates and examining the estimates for some of its key metrics.

Becton Dickinson (BDX) Q1 Earnings Surpass Estimates

Becton Dickinson (BDX) delivered earnings and revenue surprises of 12.13% and 0.64%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

Reasons to Hold West Pharmaceutical (WST) in Your Portfolio Now

West Pharmaceutical (WST) continues to gain momentum due to its strength in the Proprietary Products business. However, forex concerns persist.

MMSI or WST: Which Is the Better Value Stock Right Now?

MMSI vs. WST: Which Stock Is the Better Value Option?

West Pharmaceutical's (WST) New Launch to Expand Portfolio

West Pharmaceutical's (WST) latest addition to its portfolio is likely to address the critical need for more drug preparation and delivery options at the point of care.

Reasons to Retain West Pharmaceutical (WST) in Your Portfolio

West Pharmaceutical (WST) continues to gain momentum due to its strength in the Proprietary Products business. However, forex concerns persist.

Is Nuveen ESG Mid-Cap Growth ETF (NUMG) a Strong ETF Right Now?

Smart Beta ETF report for NUMG

Acadia Healthcare (ACHC) Q3 Earnings Beat on Patient Volumes

Acadia Healthcare's (ACHC) Q3 results benefit from growth in patient days and revenue per patient day. Management forecasts adjusted EPS, excluding income from the PRF, of $3.33-$3.43 for 2023.

Avantor (AVTR) Q3 Earnings In-Line With Estimates, Revenues Top

Despite Avantor's (AVTR) continued stability in end markets, it reports an overall soft third-quarter performance.

Integer Holdings (ITGR) Q3 Earnings Top Estimates, FY23 View Up

Integer Holdings' (ITGR) third-quarter results reflect robust Medical Sales, along with strength in the majority of the product lines.

Merit Medical (MMSI) Q3 Earnings Top Estimates, FY23 View Revised

Merit Medical (MMSI) benefits from revenue growth in both segments and all product categories within its Cardiovascular unit in the third quarter.